文献速递鼻科

度普利尤单抗体外预防IL-4诱导的鼻上皮功能改变:其疗效的证据

Dupilumab prevents nasal epithelial function alteration by IL-4 in vitro: Evidence for its efficacy.
PubMed 文献 · Int Forum Allergy Rhinol · 2024-03-11

本研究利用28例患者的鼻息肉与对照黏膜及35例慢性鼻窦炎伴鼻息肉(CRSwNP)患者的人鼻上皮细胞(HNEC),体外评估IL-4、IL-13和度普利尤单抗对上皮屏障功能、纤毛运动和伤口愈合的影响。结果显示IL-4(1、10、100 ng/mL)而非IL-13显著降低闭合蛋白和闭锁小带蛋白表达、纤毛摆动效率及伤口修复率;度普利尤单抗(0.04 mg/mL)本身对HNEC无影响,并可特异性恢复48小时IL-4刺激所致的上述上皮功能改变。

要点

  • IL-4(1、10、100 ng/mL)而非IL-13可显著降低HNEC的闭合蛋白和闭锁小带蛋白表达。
  • IL-4同样显著降低纤毛摆动效率和伤口修复率。
  • 度普利尤单抗(0.04 mg/mL)可特异性恢复IL-4刺激48小时后改变的上皮功能。

核心结论

  • 度普利尤单抗在体外通过拮抗IL-4对上皮屏障的作用(增加上皮通透性、降低纤毛摆动效率、降低伤口修复率)恢复上皮完整性。

研究设计与样本

  • 体外研究,使用28例患者的鼻息肉与对照黏膜以及35例CRSwNP患者的HNEC。
  • 在基础培养基中分别给予IL-4、IL-13和度普利尤单抗刺激48小时,评估上皮屏障功能、纤毛运动和伤口愈合。

主要发现

  • IL-4(1、10、100 ng/mL)而非IL-13诱导HNEC中闭合蛋白和闭锁小带蛋白表达、纤毛摆动效率及伤口修复率显著下降。
  • 度普利尤单抗(0.04 mg/mL)对HNEC无影响,并特异性恢复48小时IL-4刺激后改变的所有上皮功能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis with nasal polyp (CRSwNP) is a typical type 2 inflammation involving interleukin (IL)-4 and IL-13. Dupilumab is a fully human monoclonal antibody targeting IL-4 receptor α subunit, thereby blocking signaling by both cytokines. Our hypothesis was that IL-4 and IL-13, by inducing a severe epithelial dysregulation, are involved in CRSwNP pathogenesis. This study aimed to evaluate the in vitro direct effect of IL-4, IL-13, and dupilumab on nasal epithelial functions. METHODS: Nasal polyps and control mucosa from 28 patients, as well as human nasal epithelial cells (HNEC) from 35 patients with CRSwNP were used. Three major epithelial functions were investigated: the epithelial barrier function (characterized by transepithelial electrical resistance measurements and tight junction protein expression), the ciliary motion (characterized by the ciliary beating efficiency index), and wound healing (characterized by the wound repair rate) under various stimulations (IL-4, IL-13, and dupilumab). The main outcome was a significant change in epithelial functions following exposure to IL-4, IL-13, and dupilumab for 48 h in the basal media. RESULTS: IL-4 (1, 10, and 100 ng/mL) but not IL-13 induced a significant decrease in occludin and zonula-occludens protein expression, ciliary beating efficiency, and wound repair rate in HNEC. Dupilumab (0.04 mg/mL) had no effect on HNEC and specifically restored all epithelial functions altered when cells were exposed to a 48-h IL-4 stimulation. CONCLUSION: Dupilumab, in vitro, restored epithelial integrity by counteracting the effect of IL-4 on the epithelial barrier (increased epithelial permeability, decreased ciliary beating efficiency, and decreased wound repair rate).

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Fieux M, Carsuzaa F, Bellanger Y, et al. Dupilumab prevents nasal epithelial function alteration by IL-4 in vitro: Evidence for its efficacy. Int Forum Allergy Rhinol. 2024. PMID: 38465788. doi:10.1002/alr.23343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。